What Clinicians Want To Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes (Part 4 of a 4-Part Series) - Slide Archive | Research To Practice

What Clinicians Want To Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes (Part 4 of a 4-Part Series) - Slide Archive

What Clinicians Want To Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes (Part 4 of a 4-Part Series)

Please note that slides and other materials provided are for review only and not to be repurposed or published.

A 4-Part Friday Satellite Symposia Series Preceding the 63^rd ASH Annual Meeting and Exposition

Friday, December 10, 2021

MODULE 1: Front-Line Treatment for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Therapy — Alexander Perl, MD

MODULE 2: Induction and Maintenance Therapy Options for Younger Patients with AML and No Targetable Mutations — Richard M Stone, MD

MODULE 3: Optimal Treatment Approaches for AML with Targetable Mutations — Alice S Mims, MD, MSCR

MODULE 4: Management of Secondary AML (sAML); New Directions in AML Care — Geoffrey L Uy, MD

MODULE 5: Current and Future Management Approaches for Myelodysplastic Syndromes (MDS) — Harry Paul Erba, MD, PhD